Posted inPharmaceutical
India Pharma Market Growth Surges, but Datasets Disagree
India pharma market growth hit 17.1% in September per IQVIA-based research but about 13.5% per Pharmarack. Why they differ and what both agree on.
Posted inPharmaceutical
Biocon Genentech Settlement Sets Bold Pebrilzo Timeline
The Biocon Genentech settlement sets Pebrilzo launch dates: EU/UK Q1 2027, US Q3 2028, subject to approvals. What is confirmed and what is not.
Posted inPharmaceutical
Par Health Drug Recall: What the Argatroban Particle Notice Means for Hospitals
Par Health drug recall: 22 lots of argatroban injection pulled over particles. What the drug does, what hospitals must do and what the notice leaves open.
Posted inPharmaceutical
Viking Starts Phase 3 of an Oral GLP-1/GIP Treatment: What Is Proven and What Is Not
Oral GLP-1/GIP treatment VK2735 enters Phase 3 in the SUNRISE studies. What 13 weeks of tablet data show, what is unproven and what to watch next.
Posted inPharmaceutical
FDA Grants Fast Track Status to SAB-142, an Experimental Immunotherapy for Type 1 Diabetes
SAB-142 FDA Fast Track designation covers new-onset Stage 3 type 1 diabetes. Phase 2b data are due in 2H 2027; the drug is not approved.
Posted inPharmaceutical
Merck Announces Phase 3 Melanoma and Endometrial Cancer Data for ESMO 2026
Merck ESMO 2026 Phase 3 results: intismeran in melanoma and sac-TMT in endometrial cancer will be shown in full on 23-27 October. Neither is approved.
Posted inPharmaceutical
FDA Grants Breakthrough Therapy Designation to CINAINU for Alopecia Areata
CINAINU FDA Breakthrough Therapy status covers alopecia areata from age 2. It is not approval, and the company has released no efficacy figures.
Posted inPharmaceutical
Johnson & Johnson Q3 2026 Revenue Reaches $25.4 Billion as Medical Device Growth Slows
Johnson & Johnson Q3 2026 results: sales of $25.4B, up 5.9%; medicines +7.7%, MedTech +2.5%. Guidance raised, but GAAP profit fell sharply.
Posted inPharmaceutical
Roche Licenses Rona Therapeutics’ ALK7 RNAi Obesity Drug in Deal Worth Up to $1.16 Billion
Roche Rona Therapeutics obesity deal is worth up to $1.16 billion for an ALK7 RNAi candidate. Only $100M is near term, and benefit is unproven.
Posted inPharmaceutical
FDA Clears Phase 2 Trial of AK0406, a Long-Acting Influenza Prevention Drug
AK0406 FDA Phase 2 trial cleared: ArkBio will test its long-acting flu prevention candidate in a placebo-controlled study. No human efficacy data yet.